Cutaneous sarcoidosis: a new subset in the spectrum of paraneoplastic dermatoses.

CONCLUSION: Our results suggest that sarcoidosis is a new subset in the spectrum of paraneoplastic syndrome. We propose that lymphoproliferative disorders should be considered in patients with cutaneous sarcoidosis who have a poor response to conventional therapy or whose skin biopsy shows a significant number of mitoses. PMID: 29779211 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Exp Dermatol Source Type: research

Related Links:

Authors: Zhao Y, Onda K, Sugiyama K, Yuan B, Tanaka S, Takagi N, Hirano T Abstract In the present study, the antitumor effects of arsenic disulfide (As2S2) on the proliferative, survival and migratory ability of human breast cancer MCF‑7 and MDA‑MB‑231 cells were investigated, and its potential underlying molecular mechanisms with an emphasis on cell cycle arrest, apoptosis induction, autophagy induction and reactive oxygen species (ROS) generation were determined. The results indicated that As2S2 significantly inhibited the viability, survival and migration of breast cancer cells in a dose‑dependent m...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Zhuang L, Lai J, Chen K, Ding T, Yuan Y, Ma Y, Kang H, Lin Z, Fan N, Ma J, Zeng Q, Xu X, Wang Q, Chen B Abstract The aim of the present study was to prospectively evaluate the recurrence and survival outcome of primary central nervous system lymphoma (PCNSL) with intraocular involvement. For this purpose, a prospective cohort of 103 pathologically confirmed patients with PCNSL was enrolled in this study. Ophthalmologic examinations were performed both at diagnosis and during follow‑up. The patients with PCNSL with suspected intraocular involvement underwent vitrectomy for confirmation. Patients who prese...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Wu R, Yang H, Wan J, Deng X, Chen L, Hao S, Ma L Abstract Leukemia and lymphoma are common hematological malignancies in children and young adults, which pose a tremendous threat to the survival of these young patients worldwide, despite availability of various effective treatments. The Hippo pathway is a novel‑signaling pathway that regulates organ size, cell proliferation, apoptosis and tumorigenesis. The chief component of this pathway is the transducer yes‑associated protein (YAP) which is over‑expressed in numerous categories of tumors. However, little is known about the effect of YAP in hematol...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Hwang KH, Kim JH, Park EY, Cha SK Abstract Wound healing is a physiological restorative response to tissue and cell injury. This process occurs in collaboration with a complex cascade of cellular events, including biochemical alterations to the extracellular matrix. Polydeoxyribonucleotide (PDRN) is a fragmented DNA mixture from Oncorhynchus mykiss or Oncorhynchus keta sperm known to promote tissue regeneration under different pathophysiological conditions. However, the most effective molecular size of PDRNs for promoting the wound healing process and quality has not been established. In the present study,...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In conclusion, the results of the present study suggested that miR‑133a was involved in the endothelial injury process after AMI by targeting Bcl2l1. PMID: 30320356 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Paul Allen, a pioneer of personal computing, died Monday. Allen co-founded Microsoft with Bill Gates, and later bought the Seattle Seahawks. Allen had been fighting non-Hodgkin's lymphoma.
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
MONDAY, Oct. 15, 2018 -- Among patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor, progression-free survival is significantly longer in those who receive...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
A study shows thalidomide-based treatment carries risk, but could be an option for certain multiple myeloma patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
This study was aimed at the preparation of177Lu-CHX-A ″-DTPA-Rituximab injection at the hospital pharmacy for non-Hodgkin lymphoma. Rituximab was conjugated with CHX-A″-DTPA-NCS and the CHX-A″-DTPA-Rituximab conjugate was radiolabeled with177Lu in  >  95% purity. The product exhibited excellent in vitro stability up to 5 days at 37 °C. In vitro cell binding studies in Raji cells confirmed the specificity of177Lu-CHX-A ″-DTPA-Rituximab to CD20 antigen. The radioimmunoconjugate exhibited predominantly hepatobiliary clearance and low bone uptake in Swiss mice. Preliminary...
Source: Journal of Radioanalytical and Nuclear Chemistry - Category: Nuclear Medicine Source Type: research
More News: Cancer & Oncology | Dermatology | Hodgkin's Disease | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Paraneoplastic Syndrome | Sarcoidosis | Skin | Skin Biopsy | Study